Patheon Announces Official Opening of Milton Park Early Phase Development Center in Oxfordshire, UK

Toronto, Canada (April 10, 2008) – Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, today announced that it has officially opened a new early phase development facility located in Milton Park in Oxfordshire, UK.

The 13,500 square foot (1,250 square meter) leased development facility contains newly constructed formulation laboratories and a fully equipped analytical laboratory. Milton Park Operations will focus on the early phase development of solid, semi-solid and oral liquid dosage forms. The facility includes GMP manufacturing areas for the production of clinical trial materials for Phase I/II trials. Patheon’s Quick To Clinic™ programs, which accelerate molecules to clinical trials while minimizing API requirements, will be supported at the site. The new development facility holds an Investigational Medical Product License from the MHRA (UK) and is already working on a number of development projects.

“The Milton Park facility was created to meet our customer’s growing demand for rapid early phase development capacity in a strategic location”, said Norman Barras Vice-President, Pharmaceutical Development Services, Europe. “We believe that our Quick to Clinic™ approach will provide a valuable opportunity to shorten the development times of our customers’ projects.”

"Milton Park is one of many significant additions that we plan to make in our development service offerings”, added Wes Wheeler, Chief Executive Officer.  “We are constantly striving to understand our customer's needs and then respond accordingly."

ABOUT PATHEON

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 10 manufacturing and six development facilities in the United States, Canada and Europe, employing more than 4,700 people and serving a customer base of 270 pharmaceutical and biotechnology companies.

For further information: Mr. Wesley P. Wheeler, Tel:  (905) 812-2112, Fax:  (905) 812-6705, Email: wes.wheeler@patheon.com; Mr. John Bell, Chief Financial Officer, Tel: (905) 812-6812, Fax:  (905) 812-6613, Email: john.h.bell@patheon.com; Ms. Jacqueline Le Saux, General Counsel – North America and Corporate Secretary Tel:  (905) 816-3964, Fax:  (905) 812-2705; Email: jlesaux@patheon.com.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements which reflect management’s expectations regarding the Company’s future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as “plans”, “expects” or “does not expect”, “forecasts”, “anticipates” or “does not anticipate”, “believes”, “intends” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved have been used to identify these forward-looking statements. Although the forward-looking statements contained in this news release reflect management’s current assumptions based upon information currently available to management and based upon what management believes to be reasonable assumptions, the Company cannot be certain that actual results will be consistent with these forward-looking statements. Current material assumptions relate to customer volumes, regulatory compliance and foreign exchange rates. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause the Company’s actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: the market demand for client products; credit and client concentration; the ability to identify and secure new contracts; regulatory matters, including compliance with pharmaceutical regulations; international operations risks; exposure to foreign currency risks; competition; product liability claims; intellectual property; environmental, health and safety risks; substantial financial leverage; interest rates; conditions of MOVA’s tax exemptions; proposed divestiture of the Carolina site; significant shareholders; risks associated with information systems; and supply arrangements. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to update or revise them to reflect new events or circumstances.

-30-